FemPulse Receives FDA IDE Approval for Pivotal Clinical Trial
FemPulse announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering from overactive bladder (OAB).
FemPulse Completes Series C financing
FemPulse announced today the closing of its Series C financing. The company’s existing investors participated in the round, as well as two new large investors.
FemPulse Granted European Patent – Adding to US, China, and Australia
FemPulse Corporation today announced the issuance of a European patent covering its vaginally-inserted nerve stimulation technology.
Robert Taub to Represent FemPulse Series B Investors
FemPulse Corporation today announced that Robert Taub will join the Company’s board of directors as the representative of the Series B investors.
Could a doughnut-shaped nerve zapper cure overactive bladders in women?
FemPulse featured in Daily Mail article: Could a doughnut-shaped nerve zapper cure overactive bladders in women?
